Seeking Alpha

Selecta Biosciences out-licenses ImmTOR to Asklepios BioPharmaceutical

|About: Selecta Biosciences, Inc. (SELB)|By: , SA News Editor

Selecta Biosciences (NASDAQ:SELB) is up 5% premarket on robust volume in reaction to its out-licensing agreement with Asklepios BioPharmaceuticals for exclusive rights to its immune tolerance platform, ImmTOR, for use in the latter's AAV gene therapy for Pompe disease.

Under the terms of the deal, SELB is eligible to receive upfront and milestone payments up to $240M plus royalties on net sales.

Try Seeking Alpha PREMIUM for unlimited analysis on SELB